Physician profile
Colin Clark Edgerton
NPI 1245307578
$3,501,794.52
in general payments reported to CMS, 2019-2025
37 companies · $804K in 2025
The $804K reported for 2025 was more than what 99% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $151K · 2020: $112K · 2021: $371K · 2022: $539K · 2023: $14K · 2024: $1.5M · 2025: $804K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Acquisitions: $2.3M · Grant: $10K · Food and Beverage: $8,673 · Consulting Fee: $8,476 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,125 · Travel and Lodging: $315 · Education: $175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Acquisitions | $2,300,000.00 |
| Grant | $10,000.00 |
| Food and Beverage | $8,673.09 |
| Consulting Fee | $8,475.95 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,125.00 |
| Travel and Lodging | $315.27 |
| Education | $175.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| American Rheumatology Network, LLC | $3,428,745.78 | 2019-2025 | |
| Abbvie INC. | $21,793.04 | 2019-2025 | Rinvoq, Skyrizi |
| Pfizer INC. | $10,740.73 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $7,070.58 | 2019-2025 | |
| Sobi, INC | $6,381.89 | 2024-2025 | |
| Amgen INC. | $5,911.77 | 2019-2025 | Krystexxa, Tavneos, Enbrel |
| Boehringer Ingelheim Pharmaceuticals, INC. | $5,431.51 | 2019-2024 | Ofev |
| Janssen Biotech, INC. | $4,172.77 | 2019-2025 | Tremfya, Simponi Aria |
| Ucb, INC. | $3,628.10 | 2019-2025 | Bimzelx, Cimzia |
| Sandoz INC. | $1,591.08 | 2020-2025 | Hyrimoz, Jubbonti |
| Horizon Therapeutics Plc | $1,493.32 | 2020-2023 | Krystexxa |
| Astrazeneca Pharmaceuticals Lp | $1,088.31 | 2021-2025 | Saphnelo, Flumist Quadrivalent, Evusheld |
| E.R. Squibb & Sons, L.L.C. | $720.50 | 2019-2025 | Orencia |
| Glaxosmithkline, LLC. | $652.92 | 2019-2025 | Benlysta |
| Organon LLC | $411.00 | 2021-2025 | Renflexis, Hadlima, Nexplanon |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $347.43 | 2019-2025 | Taltz, Zepbound |
| Mckesson Specialty Care Distribution, LLC | $276.50 | 2019 | |
| Octapharma USA, INC. | $273.37 | 2022 | |
| Aurinia Pharma U.S., INC. | $247.12 | 2022-2024 | Lupkynis |
| Genentech USA, INC. | $160.26 | 2019-2025 | Actemra |
| Biogen, INC. | $102.62 | 2019 | |
| Genzyme Corporation | $102.39 | 2021-2023 | |
| Fresenius Kabi USA, LLC | $95.48 | 2023-2025 | Idacio |
| Alexion Pharmaceuticals, INC. | $82.86 | 2019-2024 | Strensiq |
| Ani Pharmaceuticals, INC. | $58.26 | 2025 | Purified Cortrophin Gel |
| Hikma Pharmaceuticals USA | $48.48 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $37.73 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $24.45 | 2019-2020 | |
| Kiniksa Pharmaceuticals International, Plc | $24.07 | 2024 | Arcalyst |
| Radius Health, INC. | $22.30 | 2025 | |
| Almatica Pharma LLC | $15.60 | 2025 | Teriparatide |
| Kiniksa Pharmaceuticals, Ltd. | $15.08 | 2023 | Arcalyst |
| Eyevance Pharmaceuticals LLC | $15.08 | 2021 | |
| Medexus Pharma, INC. | $12.14 | 2019 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$8,010,116.98 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Colin Edgerton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.